In 2025, the BSE Healthcare Index which is represented by mostly pharma companies underperformed the Sensex, declining ...

The rising demand for obesity drugs is prompting Indian pharma firms to pursue licensing and distribution partnerships, ...

Entering 2026, India's pharmaceutical industry initiates a crucial five-year plan to evolve into an innovation hub, aiming ...

India is expected to be the witness the fiercest competition in 2026, with Semaglutide's patent expiry in March triggering ...

After the U.S. tariff imposition, policymakers must diversify boldly, reform swiftly, and secure India’s pharma supremacy ...

Sun Pharma's Managing Director, Kirti Ganorkar, predicts that new age medicines for obesity and diabetes will drive the ...

India’s pharmaceutical exports reached USD 30.47 billion in the 2024-25 fiscal year, marking around 9.4% growth ...

India has earned global trust as the pharmacy of the world. Yet, at home, quality gaps continue to expose patients to ...

A revolution in India’s weight-loss market is coming. As Semaglutide’s patent ends in 2026, Sun Pharma, Lupin, Torrent, and ...

Access to new-age medicines for obesity and diabetes is crucial for the Indian pharmaceutical industry's growth. Combined with AI tools, this will support accessibility and affordability. India aims ...

Commerce secretary Rajesh Agrawal told officials and stakeholders that India can further consolidate its positioning in ...